Discover the unexpected link between Ixekizumab treatment for psoriatic arthritis and the rare emergence of cerebral tumefactive inflammatory lesions, shedding light on crucial treatment considerations.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Cerebral Tumefactive Inflammatory Lesion Occurrence During Ixekizumab Treatment in a Patient With Active Psoriatic Arthritis.
Marangi et al., Neurologist 2024
DOI: 10.1097/NRL.0000000000000551
Listen, folks, we’ve got something incredible here, something really tremendous. It’s about ixekizumab, a fantastic drug, really fantastic, for treating some serious conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. But here’s the deal – it’s super rare, I mean, really rare, to see central nervous system issues with this, okay? There’s been just one case before, just one, of myelitis.
Now, we had this 72-year-old guy, strong guy, but he had psoriatic arthritis. He starts on ixekizumab, and bam, a month later, he’s got numbness on the left side of his face. We do an MRI, and there’s this big lesion, really big, right where it shouldn’t be, affecting his cranial nerves. We checked everything – no cancer, no infections, nothing. So, we go in there, do a brain biopsy, because we’re thorough, and find out it’s just a bunch of histiocytes, no bad stuff.
So, we hit him with steroids, dexamethasone, a strong drug, and the guy gets better, much better. A month later, another MRI, and the lesion’s almost gone, can you believe it? It’s like magic.
But here’s the takeaway – this is the first time, the very first, we’ve seen a brain lesion with ixekizumab. It’s rare, but it tells us we’ve got to watch our patients closely, very closely, when they’re on these anti-IL-17A drugs. We’re going to keep America healthy, but we’ve got to be vigilant, always vigilant.